X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16098) 16098
Publication (2779) 2779
Book Chapter (203) 203
Book Review (122) 122
Dissertation (56) 56
Conference Proceeding (48) 48
Book / eBook (7) 7
Government Document (6) 6
Data Set (4) 4
Magazine Article (2) 2
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10734) 10734
mtor (10127) 10127
humans (7974) 7974
animals (5965) 5965
tor serine-threonine kinases - metabolism (3837) 3837
oncology (3762) 3762
rapamycin (3761) 3761
cancer (3483) 3483
mice (3344) 3344
cell biology (3310) 3310
mammalian target (3265) 3265
signal transduction (3144) 3144
phosphorylation (3106) 3106
apoptosis (3072) 3072
female (2847) 2847
male (2709) 2709
autophagy (2688) 2688
biochemistry & molecular biology (2496) 2496
activation (2391) 2391
proteins (2378) 2378
cell line, tumor (2278) 2278
akt (2268) 2268
expression (2242) 2242
signal transduction - drug effects (2134) 2134
growth (2015) 2015
proto-oncogene proteins c-akt - metabolism (1885) 1885
kinases (1875) 1875
pathway (1836) 1836
article (1725) 1725
tor serine-threonine kinases - antagonists & inhibitors (1642) 1642
tor protein (1611) 1611
analysis (1590) 1590
sirolimus - pharmacology (1580) 1580
inhibition (1509) 1509
research (1428) 1428
tor serine-threonine kinases (1379) 1379
pharmacology & pharmacy (1325) 1325
cell proliferation - drug effects (1228) 1228
phosphatidylinositol 3-kinases - metabolism (1208) 1208
metabolism (1184) 1184
pi3k (1163) 1163
cell proliferation (1139) 1139
gene expression (1129) 1129
everolimus (1120) 1120
apoptosis - drug effects (1092) 1092
neurosciences (1090) 1090
cells (1088) 1088
tumors (1057) 1057
tor serine-threonine kinases - genetics (1054) 1054
middle aged (1046) 1046
rats (1045) 1045
physiological aspects (1044) 1044
health aspects (1042) 1042
care and treatment (984) 984
proliferation (979) 979
adult (939) 939
antineoplastic agents - pharmacology (923) 923
mechanistic target of rapamycin complex 1 (888) 888
medicine, research & experimental (878) 878
cell growth (876) 876
metastasis (869) 869
signaling pathway (866) 866
biology (861) 861
mtor pathway (858) 858
cell cycle (844) 844
cells, cultured (836) 836
aged (820) 820
chemotherapy (819) 819
mutation (816) 816
genetic aspects (809) 809
kinase (796) 796
signal transduction - physiology (789) 789
survival (776) 776
therapy (773) 773
akt protein (765) 765
breast cancer (763) 763
mammalian target of rapamycin (734) 734
autophagy - drug effects (730) 730
cell line (730) 730
oxidative stress (724) 724
in-vitro (723) 723
protein kinases - metabolism (713) 713
ampk (707) 707
mice, inbred c57bl (687) 687
sirolimus - analogs & derivatives (685) 685
protein (681) 681
antineoplastic agents - therapeutic use (679) 679
immunohistochemistry (666) 666
protein kinase inhibitors - pharmacology (659) 659
mtor inhibitors (654) 654
development and progression (652) 652
research article (650) 650
disease models, animal (649) 649
sirolimus - therapeutic use (643) 643
target (643) 643
immunology (638) 638
pi3k/akt/mtor pathway (637) 637
blotting, western (626) 626
inflammation (616) 616
breast-cancer (609) 609
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16101) 16101
Chinese (73) 73
French (59) 59
Japanese (46) 46
German (23) 23
Korean (23) 23
Spanish (18) 18
Polish (12) 12
Russian (11) 11
Portuguese (2) 2
Italian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biogerontology, ISSN 1389-5729, 06/2013, Volume 14, Issue 3, pp. 303 - 23
During ageing skeletal muscles undergo a process of structural and functional remodelling that leads to sarcopenia, a syndrome characterized by loss of muscle... 
Forkhead Transcription Factors/physiology | Serpin E2/genetics | Humans | Male | Microtubule-Associated Proteins/genetics | Signal Transduction/physiology | Tripartite Motif Proteins | Young Adult | Aging/physiology | TOR Serine-Threonine Kinases/physiology | Aged, 80 and over | Adult | Female | Mice, Inbred DBA | Models, Animal | Insulin-Like Growth Factor I/physiology | Muscle Proteins/genetics | Mice, Inbred C57BL | Proto-Oncogene Proteins c-akt/physiology | Mice, Transgenic | SKP Cullin F-Box Protein Ligases/genetics | Mice, Knockout | Autophagy-Related Protein 7 | Animals | Sarcopenia/physiopathology | Adolescent | Aged | Forkhead Box Protein O1 | Mice | Muscle, Skeletal/physiology | Ubiquitin-Protein Ligases/genetics | Life Sciences | Sarcopenia | FoxO | Geriatrics/Gerontology | Ageing | mTOR | IGF1 | Akt | Developmental Biology | Cell Biology | LIFE-SPAN | IGF-I | ALPHA-V-BETA-3 INTEGRIN | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | GERIATRICS & GERONTOLOGY | GROWTH-HORMONE | MESSENGER-RNA | GENETIC-DETERMINANTS | FAST-TWITCH | CELL-CYCLE | S6 KINASE | Microtubule-Associated Proteins - genetics | SKP Cullin F-Box Protein Ligases - genetics | SKP Cullin F-Box Protein Ligases - physiology | Forkhead Transcription Factors - physiology | Ubiquitin-Protein Ligases - physiology | TOR Serine-Threonine Kinases - physiology | Muscle Proteins - physiology | Serpin E2 - physiology | Proto-Oncogene Proteins c-akt - physiology | Muscle, Skeletal - physiology | Microtubule-Associated Proteins - physiology | Muscle Proteins - genetics | Sarcopenia - physiopathology | Serpin E2 - genetics | Aging - physiology | Insulin-Like Growth Factor I - physiology | Signal Transduction - physiology | Ubiquitin-Protein Ligases - genetics | Ubiquitin | Muscles | Ligases | Proteolysis | Analysis | SKP Cullin F-Box Protein Ligases | Muscle Proteins | Aging | Serpin E2 | Signal Transduction | Biochemistry, Molecular Biology | Microtubule-Associated Proteins | Insulin-Like Growth Factor I | Proto-Oncogene Proteins c-akt | Ubiquitin-Protein Ligases | TOR Serine-Threonine Kinases | Muscle, Skeletal | Forkhead Transcription Factors | Clinical Medicine | Neurology | Neurologi | Medical and Health Sciences | Medicin och hälsovetenskap | Clinical Neurophysiology | Klinisk neurofysiologi | Klinisk medicin
Journal Article
Annual Review of Medicine, ISSN 0066-4219, 1/2016, Volume 67, Issue 1, pp. 11 - 28
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene... 
lymphoproliferative disorders | mammalian target of rapamycin (mTOR) | mutation | breast cancer | phosphoinositide 3-kinase (PI3K) AKT | pathway inhibitors | Mammalian target of rapamycin (mTOR) | Phosphoinositide 3-kinase (PI3K)/AKT | Breast cancer | Lymphoproliferative disorders | Mutation | Pathway inhibitors | MEDICINE, RESEARCH & EXPERIMENTAL | PIK3CA MUTATIONS | PHOSPHATIDYLINOSITOL 3-KINASE | TYROSINE KINASE | ESTROGEN DEPRIVATION | phosphoinositide 3-kinase (PI3K)/AKT | PHOSPHOINOSITIDE 3-KINASE | RENAL-CELL CARCINOMA | POSITIVE BREAST-CANCER | MAMMARY-TUMORS | CHRONIC LYMPHOCYTIC-LEUKEMIA | UP-REGULATION | TOR Serine-Threonine Kinases - metabolism | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Antineoplastic Agents - therapeutic use | Receptors, Estrogen - analysis | Receptor Protein-Tyrosine Kinases - metabolism | Breast Neoplasms - drug therapy | Proto-Oncogene Proteins c-akt - genetics | TOR Serine-Threonine Kinases - antagonists & inhibitors | Breast Neoplasms - chemistry | Phosphatidylinositol 3-Kinase - genetics | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Female | Lymphoproliferative Disorders - drug therapy | Receptor, ErbB-2 - analysis | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Care and treatment | Protein kinases | Health aspects | Methods | Cancer
Journal Article
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 03/2015, Volume 9, pp. 1555 - 1584
Osteosarcoma (OS) is the most common malignant bone tumor occurring mostly in children and adolescents between 10 and 20 years of age with poor response to... 
ALS | Osteosarcoma | Autophagy | EMT | PI3K/Akt/mTOR pathway | Apoptosis | CHEMISTRY, MEDICINAL | autophagy | EMT TRANSCRIPTION FACTORS | apoptosis | PHARMACOLOGY & PHARMACY | SIRTUINS | CANCER | osteosarcoma | FAMILY | Reactive Oxygen Species - metabolism | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Phosphatidylinositol 3-Kinases - metabolism | Structure-Activity Relationship | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Autophagy - drug effects | Pyrimidines - chemistry | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Azepines - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | Cell Survival - drug effects | Mitochondria - metabolism | Mitochondria - drug effects | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Azepines - pharmacology | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Cell Cycle - drug effects | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Screening Assays, Antitumor | Mitogen-Activated Protein Kinases - metabolism | Development and progression | Genetic aspects | Cellular signal transduction | Gene expression | Health aspects | Crosstalk | Nuclear engineering | AKT protein | Aurora kinase | Metastasis | Cancer therapies | Anticancer properties | Proteins | Signal transduction | Mitochondria | N-Cadherin | Surgery | Biocompatibility | Inhibition | Stress response | AMP | Mortality | MAP kinase | Rapamycin | Metabolism | 1-Phosphatidylinositol 3-kinase | Nuclear safety | Chemotherapy | Hospitals | Inhibitors | Phagocytosis | TOR protein | Adolescence | Biotechnology | Oxidative stress | Mesenchyme | Laboratories | Bone tumors | Activation | Kinases | E-cadherin | Cyclin B1 | Cell adhesion & migration | Pathways | Cell cycle | Children | Trends | Inducers | Phenotypes | Signaling | Bone cancer | Cell death | Cell lines
Journal Article
Journal Article
Acta Pharmaceutica Sinica B, ISSN 2211-3835, 09/2015, Volume 5, Issue 5, pp. 378 - 389
Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target. Many recent studies have provided convincing evidences of strong... 
Cancer drug discovery and development | HIF-1α inhibitors | HIF-1α | TRANSCRIPTIONAL ACTIVITY | DNA-BINDING | HIF-1 alpha | PROTEASOMAL DEGRADATION | FACTOR-I | ANTITUMOR-ACTIVITY | SIGNAL-TRANSDUCTION | SMALL-MOLECULE INHIBITORS | TUMOR-SUPPRESSOR PROTEIN | PHARMACOLOGY & PHARMACY | HIF-1 alpha inhibitors | HYPOXIA-INDUCIBLE FACTOR-1 | ENDOTHELIAL GROWTH-FACTOR | RCC, renal cell carcinoma | Ras, rat sarcoma | Raf, rapidly accelerated fibrosarcoma | EGF, epidermal growth factor | C-TAD, COOH-terminal TAD | HTS, high throughput screens | ARD-1, arrest-defective-1 | ELISA, enzyme-linked immunosorbent assay | pVHL, von Hippel-Lindau protein | LEP, leptin | ChIP, chromatin immunoprecipitation | IPAS, inhibitory PAS | IGF-BP3, IGF-factor-binding protein 3 | PAS, Per and Sim | mTOR, mammalian target of rapamycin | RT-PCR, reverse transcription polymerase chain reaction | CAC, circulating angiogenic cells | CoCl2, cobalt chloride | AKt, protein kinase B | TPT, topotecan | bHLH, basic-helix-loop-helix | LDHA, lactate dehydrogenase | GLUTs, glucose transporters | P, proline residue | ODDD, oxygen dependent degradation domain | TGF-α, transforming growth factor α | VEGF, vascular endothelial growth factor | CPTs, camptothecins | Mdm2, mouse double minute 2 homolog | PKM, pyruvate kinase M | AhR, aryl hydrocarbon receptor | K, lysine residue | IGF2, insulin-like growth factor 2 | GLUT3, glucose transporter 3 | CBP associated factor | eIF-4E, eukaryotic translation initiation factor 4E | MEK, MAPK | ADM, adrenomedullin | ARNT, aryl hydrocarbon nuclear translocator | HK2, hexokinase 2 | PHDs, prolyl-4-hydroxylases | PCAF, p300 | FIH-1, factor inhibiting HIF-1 | Review | SIRT 1, Sirtuin 1 | ERK kinase | C-MYC, myelocytomatosis virus oncogene cellular homolog | IGF-BP2, IGF-factor-binding protein 2 | N, asparagine residue | TAD, transactivation domains | HDAC, histone deacetylase | EMSA, electrophoretic mobility shift assay | LRP1, LDL-receptor-related protein 1 | Luc, luciferase | GAs, geldanamycins | HIF-1α, hypoxia-inducible factor-1α | HK1, hexokinase 1 | ID2, DNA-binding protein inhibitor | HPH, HIF-1 prolyl hydroxylases | NOS, nitric oxide synthase | N-TAD, NH2-terminal TAD | MNK, MAP kinase interacting kinase | MTs, microtubules | HRE, hypoxia response elements | ERK, extracellular signal-regulated kinase | EPO, erythropoietin | MAPK, mitogen-activated protein kinases | PI3K, phosphatidyl inositol-4,5-bisphosphate-3-kinase | DFO, deferoxamine | Top I, topoisomerase I | GLUT1, glucose transporter 1 | Hsp90, heat shock protein 90 | TGF-β3, transforming growth factor beta3 | 4E-BP1, eukaryotic translation initiation factor 4E (eIF-4E) binding protein p70 S6 kinase (S6K) | GA, geldanamycin
Journal Article
Journal Article
Journal Article